Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- Trial result
Pancreatic cancer
Niraparib (PARP inhibitor) Delivers 4.4-mo mPFS in DDR-Altered Advanced Pancreatic Cancer (NIRA-PANC)
Niraparib is an oral PARP1/2 inhibitor tested as monotherapy in an open-label, single-arm Phase II study (NIRA-PANC; NCT03553004) for metastatic or unresectable pancreatic cancer with germline or somatic DDR…
NCT03553004 - Trial result Spotlight
Colorectal cancer
EC (encorafenib+BRAF inhibitor) + cetuximab (EGFR mAb) + FOLFIRI cuts PFS risk ~56% in 1L BRAF V600E mCRC
Encorafenib (BRAF inhibitor) plus cetuximab (EGFR antibody) was combined with FOLFIRI chemotherapy as first-line treatment in BREAKWATER Cohort 3 (Phase 3, open-label; NCT04607421) for untreated BRAF V600E–mutant…
NCT04607421 - Trial result
Colorectal cancer
ctDNA (MRD)-guided ACT (capecitabine±oxaliplatin) cuts 3-year recurrence in stage II MSS colon cancer
CIRCULATE (AIO KRK-0217/ABCSG; NCT04089631) used a tumor-informed NGS ctDNA assay post-op in stage II pMMR/MSS colon cancer: ctDNA+ patients were randomized to adjuvant chemotherapy (6 mo capecitabine or 3–6 mo…
NCT04089631 - Trial result
Colorectal cancer
Nivolumab + ipilimumab (PD-1 + CTLA-4) improves long-term treatment-free survival vs nivolumab in MSI-H/dMMR mCRC
Nivolumab + ipilimumab (NIVO + IPI), a dual immune checkpoint regimen targeting PD-1 and CTLA-4, was compared with nivolumab (PD-1) monotherapy in the Phase 3 CheckMate 8HW trial in metastatic colorectal cancer with…
NCT04008030 - Trial result Spotlight
Brain and CNS tumors
Cesium-131 tile brachytherapy (TBRT) slashes surgical-bed recurrence vs post-op SRT in resected brain mets
ROADS (NCT04365374) was an open-label, randomized Phase 3 trial across 32 US centers comparing resection + post-operative stereotactic radiation therapy (SRT; standard approach for cavity control) vs resection +…
NCT04365374 - Trial result
Chronic myeloid leukemia
Asciminib (ABL myristoyl-pocket “STAMP” inhibitor) sustains deeper molecular responses vs frontline ATP-competitive TKIs in ASC4FIRST (wk 144)
Asciminib (ASC) is a first-in-class allosteric BCR::ABL1 inhibitor that binds the ABL myristoyl pocket (vs ATP-site TKIs like imatinib/dasatinib/nilotinib/bosutinib). In the multicenter open-label Phase 3 ASC4FIRST…
NCT04971226 - Trial result
Bladder and urothelial cancer
Zelenectide pevedotin (BT8009) Nectin-4–targeted BDC + pembrolizumab hits 50% cORR and 13.0-mo mPFS in 1L cisplatin-ineligible la/mUC
Zelenectide pevedotin (zele; BT8009) is a Nectin-4–targeted Bicycle Drug Conjugate delivering MMAE (small 4.2 kDa construct with short plasma half-life), combined here with PD-1 blockade (pembrolizumab) in Duravelo-1…
NCT04561362 - Trial result
Multiple solid tumors
ALK201 FGFR2b ADC posts 24% ORR in refractory solid tumors with low ocular toxicity
ALK201 is a first-in-human FGFR2b-targeting antibody–drug conjugate from Allink Biotherapeutics, using a humanized anti-FGFR2b monoclonal antibody linked to the topoisomerase-I payload exatecan via a cleavable…
NCT06656390 - New trial Spotlight
Kidney cancer
Phase 3 MO-03 live biotherapeutic (butyrate‑producing Clostridium butyricum ) added to PD‑1/CTLA‑4±VEGFR TKI first-line ccRCC
This SWOG Cancer Research Network Phase 3 double-blind, placebo-controlled trial (BioFront; also listed as SWOG S2419) tests whether MO-03—a live biotherapeutic containing a butyrate‑producing bacterium *Clostridium…
NCT07383441 Registrational - New trial
Lymphoma
Phase 2 epcoritamab CD3×CD20 bispecific T‑cell engager plus DA‑EPOCH‑R in high‑risk Burkitt lymphoma
This Phase 2 BEDROCK study tests whether adding epcoritamab (Epkinly; a subcutaneous CD3×CD20 bispecific antibody that redirects T cells to kill CD20+ B‑cell lymphoma) can improve outcomes when layered onto…
NCT07662928 Exploratory - New trial
Small cell lung cancer
Phase 3 trilaciclib CDK4/CDK6 inhibitor tests myeloprotection in limited-stage SCLC.
This Phase 3 randomized, double-blind, placebo-controlled, parallel-group trial sponsored by Pharmacosmos A/S tests whether trilaciclib—a small-molecule CDK4/CDK6 inhibitor that transiently arrests hematopoietic…
NCT07473128 Registrational - New trial Spotlight
Non-small cell lung cancer
Phase 3 CAN-2409 HSV-tk adenoviral gene therapy + prodrug with PD-1 blockade in NSCLC
Candel Therapeutics’ Phase 3 AURORA trial randomizes patients 1:1 to either intratumoral aglatimagene besadenovec (CAN-2409)—a replication-deficient adenoviral vector delivering the HSV-tk “suicide gene”—plus oral…
NCT07660094 Registrational - New trial
Non-small cell lung cancer
Phase 3 Atezolizumab PD-L1 inhibitor (± hyaluronidase for SC delivery) after Stage I NSCLC resection
National Cancer Institute (NCI) is running AASI-NSCLC, a randomized Phase 3 adjuvant study testing whether 1 year of anti–PD-L1 immunotherapy reduces recurrence after complete (R0) surgery for Stage IA3 or IB NSCLC…
NCT07388524 Registrational - New trial Spotlight
Multiple myeloma
Phase 3 linvoseltamab BCMA×CD3 bispecific antibody versus daratumumab anti-CD38 in high-risk SMM.
This Phase 3, randomized, open-label study (LINKER-SMM2) tests whether Regeneron’s linvoseltamab-gcpt—an off-the-shelf T-cell–engaging bispecific monoclonal antibody that binds BCMA on plasma cells and CD3 on T…
NCT07393282 Registrational - New trial
Pancreatic cancer
Phase 1 ELI-002 7P KRAS-targeted amphiphile peptide vaccine with mFOLFIRINOX ± PD-1 blockade
This Memorial Sloan Kettering Cancer Center–led, open-label, multi-institution pilot study tests neoadjuvant mFOLFIRINOX (5-FU/leucovorin + irinotecan + oxaliplatin cytotoxic chemotherapy) combined with ELI-002 7P,…
NCT07671339 Exploratory - New trial
Acute myeloid leukemia and MDS
Phase 1 CRD3874-SI allosteric STING agonist (TMEM173) in relapsed/refractory AML.
This Memorial Sloan Kettering Cancer Center–sponsored Phase 1 study tests escalating dose levels of CRD3874-SI, an intravenous small-molecule STING (TMEM173) agonist designed to activate innate immune signaling and…
NCT07661095 Exploratory - New trial
Bladder and urothelial cancer
Phase 1b/2 quemliclustat CD73 adenosine-pathway inhibitor with EV nectin-4 ADC + pembro PD‑1
Fred Hutchinson Cancer Center is running a Phase 1b/2 study adding quemliclustat (a CD73 inhibitor that aims to reduce immunosuppressive adenosine signaling in the tumor microenvironment) to the now-established…
NCT07667335 Exploratory - New trial
Neuroendocrine and adrenal tumors
Phase 1 211At‑MABG targeted alpha radiotherapy (NET/norepinephrine transporter–avid) in advanced NETs
University of Pennsylvania is running a first-in-human Phase 1, open-label, single-group dose-escalation (standard 3+3) study with an RP2D expansion cohort to evaluate fractionated intravenous 211At‑MABG…
NCT07661420 First-in-human - New trial
Colorectal cancer
Phase 2 tovecimig DLL4×VEGF bispecific antibody plus FOLFIRI in second-line metastatic CRC.
This open-label Phase 2 investigator-sponsored study evaluates whether adding tovecimig—Compass Therapeutics’ DLL4- and VEGF-directed bispecific monoclonal antibody (dual angiogenesis / Notch-pathway modulation)—can…
NCT07662031 Exploratory - New trial
Liver and bile duct cancer
Phase 3 D07001 oral gemcitabine (deoxycytidine antimetabolite) + capecitabine in advanced BTC
In this Phase 3, randomized, double-blind, placebo-controlled, multicenter study (Inno-GO-07), InnoPharmax is testing whether adding D07001-softgel capsules—an oral gemcitabine formulation (a deoxycytidine analog…
NCT06622057 Registrational - New trial
Multiple solid tumors
Phase 1 GS-2426 MAT2A small‑molecule inhibitor in MTAP‑deleted advanced solid tumors
This Phase 1, multicenter, open-label Gilead Sciences study evaluates GS-2426, a small-molecule inhibitor of methionine adenosyltransferase 2A (MAT2A), in adults with advanced/metastatic solid tumors harboring MTAP…
NCT07601243 Exploratory - New trial
Multiple solid tumors
Phase 1 MR-guided SBRT (adaptive MR-guided radiotherapy) single-fraction metastasis ablation
This single-arm Phase 1 study (“ONE SHOT”) evaluates feasibility, safety/tolerability, and early local control signals for single-fraction adaptive MR-guided stereotactic body radiation therapy (SBRT) in patients…
NCT07671768 Exploratory - New trial
Multiple solid tumors
Phase 2 gemcitabine + mitomycin C cytotoxics with thalidomide anti-angiogenic immunomodulator
This open-label, single-arm Phase 2 study sponsored by Sarcoma Oncology Research Center, LLC evaluates a “metronomic” (frequent, lower-dose) combination intended to balance disease control with tolerability in…
NCT07671534 Exploratory - Trial result Spotlight
Kidney cancer
Pembrolizumab (PD-1) + high-dose IL-2 (T-cell–activating cytokine) drives 42% CRs and >84-mo OS in 1L ccRCC
Pembrolizumab (anti–PD-1) combined with high-dose interleukin-2 (aldesleukin; pleiotropic T-cell/NK-cell activating cytokine) was evaluated as a fixed-duration, single-arm Phase 2 regimen in treatment-naive advanced…
NCT02964078 - Trial result Spotlight
Kidney cancer
CaboNivo (cabozantinib VEGFR/MET/AXL TKI + nivolumab PD-1) drives 43% ORR in metastatic non–clear cell RCC—chromophobe remains refractory
Cabozantinib (a multikinase VEGFR/MET/AXL inhibitor) plus nivolumab (PD-1 antibody) was evaluated in an investigator-initiated Phase 2 study in advanced/metastatic non–clear cell RCC with 0–1 prior systemic therapies…
NCT03635892 - Trial result Spotlight
Kidney cancer
CBM588 (Clostridium butyricum live biotherapeutic) + ICB combos drives big PFS/ORR gains in dysbiotic 1L mRCC
CBM588 is an oral *Clostridium butyricum*–based live biotherapeutic intended to modulate the gut microbiome; here it was added to standard first-line immune checkpoint–based regimens (nivolumab/ipilimumab or…
NCT03829111 - Trial result
Kidney cancer
Sunitinib (VEGFR TKI) Response in mccRCC Tracks with Pro-inflammatory TME; DSP Signature Predicts Benefit
Sunitinib is an oral VEGFR/PDGFR/KIT tyrosine kinase inhibitor; in this Phase 2 single-arm trial in metastatic clear cell RCC treated peri-cytoreductive nephrectomy (NCT00715442), 46 patients underwent spatial…
NCT00715442 - Trial result
Kidney cancer
Cabozantinib (VEGFR/MET/AXL TKI) + nivolumab (PD-1) doubles PFS in aRCC with baseline bone metastases vs sunitinib
Cabozantinib plus nivolumab (C+N) combines multi-kinase VEGFR/MET/AXL inhibition with PD-1 blockade and was compared with sunitinib in the Phase 3 CheckMate-9ER first-line clear-cell aRCC trial (NCT03141177; N=651);…
NCT03141177 - Trial result
Kidney cancer
AI-quantified high-branching tumor vasculature (H&E) stratifies recurrence risk beyond TNM in adjuvant RCC
In a post-hoc biomarker analysis of CheckMate 914 (CM914; NCT03138512), an adjuvant randomized Phase 3 trial after nephrectomy in localized/high-risk RCC, investigators used a deep-learning model on H&E whole-slide…
NCT03138512 - Trial result
Kidney cancer
Radium-223 (bone-seeking alpha emitter) + cabozantinib (VEGFR/MET/AXL TKI) misses SSE-free survival in RCC bone metastases
Radium-223 dichloride is a bone-targeted alpha-emitting radiopharmaceutical, and cabozantinib is a multikinase VEGFR/MET/AXL inhibitor with known activity in RCC bone disease; RADICAL (Alliance A031801; NCT04071223)…
NCT04071223
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.